Navigation Links
National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Date:8/19/2007

MOUNTAINSIDE, N.J., Aug. 14 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI.PK), today announced that Michael Cohen, CEO of the Company, and Jacob Cohen, have discovered biomaterial derived from non- embryonic stem cells, which appears to promote tissue repair in various wound care applications.

On July 26, 2007, the Company announced that while using its proprietary embryonic stem cell lines, Michael and Jacob Cohen discovered a group of biomaterials that in preclinical studies appear to increase the rate at which the tissue surrounding a wound heals, and ultimately, the strength of such newly formed tissue. Today, the Company reports that Michael and Jacob Cohen have also been able to derive such tissue repair promoting biomaterials from non-embryonic stem cells, such as umbilical cord blood cells.

The Company has filed provisional patent applications with the United States Patent and Trademark Office, which cover both the July 26, 2007 discovery and the discovery announced today.

According to Michael Cohen "By deriving these novel biomaterials from non- embryonic stem cells, such as umbilical cord blood, we believe we can avoid the costly and time consuming procedures that plague therapies developed from embryonic stem cells. This new discovery gives us the ability to cultivate tissue repair and wound healing products and commence clinical trials of such products in an expedited manner."

National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics, with a particular focus on finding a cure for diabetes. In addition to its work with stem cell therapeutics, the Company is working to leverage the commercial infrastructure and product development capabilities of its wholly-owned subsidiary, The Sperm Bank of NY. The Company's investigational products a
'/>"/>

SOURCE National Stem Cell Holding, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
7. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
8. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...ery-USMarketTrends&Analysis http://www.report...Market-Trends--Analysis.html ,, TheUSintranasa...euticapplicationsfromthedeliveryofconventionalloca...cdrugs.Thefutureofthetechnologyhingesontotheeffect...
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 1EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 3Statewide program to improve emergency care for children 54567 1Statewide program to improve emergency care for children 54567 2Scientists take early steps toward mapping epigenetic variability 9583 1Scientists take early steps toward mapping epigenetic variability 9583 2
...udy to Show That Extended,Thromboprophylaxis Reduc... Statistically Significant 44% , PARIS, July 8, 20...ed today the results of the EXCLAIM (EXtended CLin...study, which showed,the benefit of extended prophy... mobility by demonstrating the superiority of 5 we...
...Inc. (NASDAQ:INSM), a ,biopharmaceutical company f...r the treatment of metabolic diseases with unmet,...nt at this,week,s C.E. Unterberg, Towbin (CEUT) Em... City. , The conference, to be held at the Mand...om Tuesday, July 10th through Thursday,July 12th....
Other Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...Endorsements,Business,andPressJoinEfforttoEducate ...--Onceagain,theNationalBipolarFoundationandtheMedi..."Safe,tilStable"program,whichisnowbeingwidelyaccep...r.Today,theNationalBipolarFoundationreceivedaprocl...romtheLt.GovernorofLouisianaMitchLandrieu.TheNatio...
(Date:11/25/2009)...ery that grew out of a collaboration between UCLA ...ope to the nearly 10 million Americans who suffer ...wn as hardening of the arteries, peripheral arteri...m in which narrowed arteries reduce blood flow to ...for vascular disease, heart attack and stroke, and...
(Date:11/25/2009)... to fight rheumatoid arthritis, could help newly d...ESDAY, Nov. 25 (HealthDay News) -- A drug commonly...id arthritis now also shows some promise in helpin..., The drug, rituximab (Rituxan), helped patients...ough the disease had destroyed some of their pancr...
(Date:11/25/2009)... by neurological symptoms, study finds , ...gical side effects are among the potential problem...r who were treated with cisplatin-based chemothera... 1,409 Norwegian men treated for unilateral testic... a follow-up survey conducted from 1998 to 2002. ,...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
... by the researchers now reckons the evil effects o... protects against the development of brain tumors ...s done a couple of years ago , an unexpected findi...// The recent study undwells the fact that g...
...al engineering team has announced the development ... person,with an ability to deliver a visual acuity...ature television camera and an ultrasonic distance... processing the video and distance signals,// the ...
...ng history of sorts, doctors in Ohio, the United S...ar vein to a man to rid him of a painful ulcer due...his is the first time a bovine vein is used in man...ceeded very well. Dr. Hugh Beebe, the center's dir...
...chers at the Georgetown University Lombardi cancer...a protein that they say, is responsible for the sp...lled Pa 28 alpha, can also cause the spread of oth... To isolate the protein, Ngaiza and colleagues ...
...test in cardiology is OCT, which expands into Opti...de many cardiologists sit up and take notice and i...oped by Dr. Brett Bouma an assistant professor at ...ound and will allow cardiologists to view the stat...
...reakthrough using gene therapy mouthwash promises ...hwash wards off oral cancer by destroying suspicio...nt. The idea is to attack the pre-cancerous patche...nthusiastic, as the patches have disappeared compl...
Other Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
Ultimum Introducers
Irrigating Cannula Handpiece (Titanium)
Stronger Irrigation/Aspiration Cannula
... are designed for endomyocardial biopsies. The r... of a 3-pull ring handle, stainless steel cutting ...rotates to accommodate any position. ,A spring in...s are opened by moving the double rings away from ...
Medicine Products: